文献速递脊柱关节炎

甲氨蝶呤单药治疗早期银屑病关节炎的持续MDA达成率及IL-23驱动特征

Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis.
PubMed 文献 · RMD Open · 2020-01-01

本研究基于荷兰西南部早期银屑病关节炎队列,分析新诊断PsA患者起始甲氨蝶呤(MTX)单药治疗的应答情况。219例患者中183例(84%)在诊断6个月内起始MTX单药,90例全程使用MTX单药1年者中44例(24%)在6个月达到MDA、33例(18%)在1年时仍维持MDA;未应答者基线和治疗期间的IL-23与IL-10浓度显著更高。

要点

  • 早期PsA中仅18%患者MTX单药1年时维持MDA。
  • MTX未应答者基线和治疗中IL-23、IL-10浓度显著更高。
  • 结果提示PsA需更积极的达标治疗和个体化策略。

核心结论

  • 新诊断PsA患者中仅18%在MTX单药治疗1年时处于持续MDA。
  • MTX未应答者更常见IL-23驱动性疾病。

研究设计与样本

  • 基于荷兰西南部早期银屑病关节炎队列研究(Early Psoriatic Arthritis cohoRt),纳入少关节炎或多关节炎且随访至少1年的PsA患者。
  • 分析起始并持续MTX单药治疗1年患者的6个月疾病活动度,并用珠基多免疫分析检测基线及3、6个月细胞因子谱。

主要发现

  • 219例患者中183例(84%)在诊断6个月内起始MTX单药治疗。
  • 90例全程使用MTX单药1年者中44例(24%)在6个月达到MDA,1年时降至33例(18%)。
  • 未应答者基线和MTX治疗期间IL-23与IL-10浓度显著更高。

关键数值与推荐

  • MDA达成率:6个月24%(44/90),1年18%(33/90)。
  • MTX单药起始率:诊断6个月内84%(183/219)。

临床怎么用

  • 对早期PsA起始MTX单药治疗时应预期1年持续MDA率较低,需早期评估应答并考虑达标治疗策略。
  • IL-23和IL-10升高可能提示MTX应答不佳,支持个体化治疗选择。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study describes the response to MTX monotherapy in newly diagnosed patients with PsA in usual care. Second, we compared clinical variables and cytokine profiles in patients responding and not responding to MTX monotherapy. METHODS: We used data collected in the Dutch southwest Early Psoriatic Arthritis cohoRt study to select patients with PsA with oligoarthritis or polyarthritis, and at least 1 year follow-up. We analysed disease activity at 6 months of patients who started MTX monotherapy and still used MTX monotherapy 1 year after diagnosis. Cytokine profiles were determined at baseline and after 3 and 6 months with a bead-based multi-immunoassay. RESULTS: We identified 219 patients of which 183 (84%) patients started MTX monotherapy within 6 months after diagnosis. 90 patients used MTX monotherapy throughout the first year of which 44 patients (24%) reached minimal disease activity(MDA) at 6 months, decreasing to 33 patients (18%) after 1 year. Non-responders had significantly higher concentrations of interleukin (IL) 23 and IL-10 before and during MTX therapy. CONCLUSIONS: Our results showed that only 18% of patients with PsA are in sustained MDA after 1 year of MTX monotherapy and non-responders more often had IL-23-driven disease. Our results indicate the need for more treat-to-target and personalised therapy strategies in PsA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. den Braanker H, Wervers K, Mus AMC, et al. Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis. RMD Open. 2020. PMID: 32669451. doi:10.1136/rmdopen-2020-001175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。